Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients

Clinical Chemistry and Laboratory Medicine : CCLM
Massimo TempestilliLeopoldo Paolo Pucillo


Ebola virus, an enveloped virus, is the cause of the largest and most complex Ebola virus disease (EVD) outbreak in West Africa. Blood or body fluids of an infected person may represent a biohazard to laboratory workers. Laboratory tests of virus containing specimens should be conducted in referral centres at biosafety level 4, but based on the severity of clinical symptoms, basic laboratories might be required to execute urgent tests for patients suspected of EVD. The aim of this work was to compare the analytical performances of laboratory tests when Triton X-100, a chemical agent able to inactivate other enveloped viruses, was added to specimens. Results of clinical chemistry, coagulation and haematology parameters on samples before and after the addition of 0.1% (final concentration) of Triton X-100 and 1 h of incubation at room temperature were compared. Overall, results showed very good agreement by all statistical analyses. Triton X-100 at 0.1% did not significantly affect the results for the majority of the analytes tested. Triton X-100 at 0.1% can be used to reduce the biohazard in performing laboratory tests on samples from patients with EVD without affecting clinical decisions.


Aug 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P UkkonenK Hedman
Sep 1, 1984·Journal of Clinical Microbiology·S W Mitchell, J B McCormick
Apr 24, 2004·Clinical Chemistry·Martin HersbergerArnold von Eckardstein
Nov 19, 2010·Lancet·Heinz Feldmann, Thomas W Geisbert
Jul 23, 2011·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Peter Hellstern, Bjarte G Solheim
Jun 1, 2012·The Journal of Hospital Infection·H C MaltezouUNKNOWN EuroNHID Working Group
Nov 6, 2012·Annual Review of Pathology·Slobodan Paessler, David H Walker
Oct 18, 2014·Clinical Chemistry and Laboratory Medicine : CCLM·Giuseppe LippiMario Plebani
Oct 19, 2014·BMJ : British Medical Journal·Anne Gulland

❮ Previous
Next ❯


Sep 30, 2017·The Journal of Infectious Diseases·Jeroen J A van KampenMarion P G Koopmans
Feb 13, 2016·Journal of Clinical Microbiology·Todd A. CuttsSteven S Theriault
Apr 20, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·Jeroen P H M van den WijngaardChrista M Cobbaert
Feb 7, 2019·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Barbara BartoliniAntonino Di Caro
May 17, 2018·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Chantal B ReuskenMarion Koopmans
Nov 6, 2018·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M M RemyF Suter-Riniker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

African Journal of Medicine and Medical Sciences
O Baiyewu
Médecine sciences : M/S
Olivier ReynardChristophe Peyrefitte
African Health Sciences
Beuy Joob, Viroj Wiwanitkit
© 2021 Meta ULC. All rights reserved